Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  C R Bard Inc    BCR

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

BARD(CR) : Bard Announces Agreement to Acquire Medivance, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/25/2011 | 10:15pm CET

C. R. Bard, Inc. (NYSE: BCR) today announced that it has reached a definitive agreement to acquire Medivance, Inc. for a purchase price of approximately $250 million. The transaction will be structured as a merger subject to the satisfaction of customary conditions, including Hart-Scott-Rodino clearance. Upon completion of the merger, the Medivance organization will become part of Bard Medical division.

Medivance, located in Louisville, Colorado, is the market leader in the field of therapeutic hypothermia. In recent years, accurate manipulation of body temperature to targeted levels has emerged as an effective treatment option for a variety of critically ill patients. The American Heart Association, The American Stroke Association, The Brain Trauma Foundation and various international medical associations have issued therapeutic hypothermia guidelines as the clinical data supporting Targeted Temperature Management? has grown. Medivance's Arctic Sun® family of products provides clinicians with a powerful technology to effectively manage patient temperature in a non-invasive manner.

Timothy M. Ring, chairman and CEO, commented, "With their unique and proprietary technology, Medivance is the market leader in an emerging and growing space. This merger is a great strategic fit for Bard as Medivance's Targeted Temperature Management? product line is synergistic with our critical care sales call point, and their technology efficiently addresses a large unmet need in a market that is growing double digits. This acquisition represents an important building block for our critical care product offering."

Based on the anticipated completion of the merger in the fourth quarter of 2011, Bard expects the dilution impact to be immaterial to earnings per share in 2011.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate", "estimate", "expect", "project", "intend", "forecast", "plan", "believe", and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our June 30, 2011 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

C. R. Bard, Inc.
Investor Relations:
Todd W. Garner, 908-277-8065
Vice President, Investor Relations
or
Media Relations:
Scott T. Lowry, 908-277-8365
Vice President and Treasurer


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on C R BARD INC
01/07 C R BARD : Greenberg Traurig Trial Victory Named Top Defense Verdict of 2016
01/06 C R BARD : Greenberg Traurig Trial Victory Named Top Defense Verdict of 2016
01/04 C R BARD : Bard to Host Earnings Conference Call on January 26, 2017
01/03 C R BARD : Bard to Present at J. P. Morgan Healthcare Conference
2016 C. R. BARD, INC. (NYSE : BCR) Files An 8-K Amendments to Articles of Incorporati..
2016 C R BARD : How These Medical Instruments Stocks are Faring? -- Cooper, Insulet, ..
2016 BARD C R INC /NJ/ : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Y..
2016 C R BARD : Bard Declares Quarterly Dividend
2016 C R BARD : Lori Cohen, Head of Greenberg Traurigs Trial Practice, Chosen as a Na..
2016 C R BARD : Lori Cohen, Head of Greenberg Traurig's Trial Practice, Chosen As Nat..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
01/17DJLUXOTTICA FOUNDER : A Lifetime of Deals -- WSJ
01/17DJLUXOTTICA : Merger to Create Eyewear Giant -- WSJ
01/17DJWHAT'S NEWS : Business & Finance -- WSJ
01/16 ESSILOR INTL : Luxottica's merger helps Del Vecchio manage family risks
01/16DJLUXOTTICA : Another Big Splash by Italy's Eyewear King
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
01/08 BECTON, DICKINSON : Does This Dividend Aristocrat Measure Up To Its Peers?
01/05 The 'Best' And 'Worst' Dividend Aristocrats Of 2016
01/05 Premarket analyst action
01/03 Today's analyst action
01/03 C.R. BARD : Leader Or Laggard?
Advertisement
Financials ($)
Sales 2016 3 702 M
EBIT 2016 1 064 M
Net income 2016 688 M
Debt 2016 407 M
Yield 2016 0,42%
P/E ratio 2016 29,82
P/E ratio 2017 22,53
EV / Sales 2016 4,77x
EV / Sales 2017 4,46x
Capitalization 17 263 M
More Financials
Chart C R BARD INC
Duration : Period :
C R Bard Inc Technical Analysis Chart | BCR | US0673831097 | 4-Traders
Full-screen chart
Technical analysis trends C R BARD INC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 246 $
Spread / Average Target 4,7%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Tim M. Ring Chairman & Chief Executive Officer
John H. Weiland President, Chief Operating Officer & Director
Christopher S. Holland Chief Financial Officer & Senior Vice President
John A. DeFord Senior VP-Science, Technology & Clinical Affairs
Patricia G. Christian VP-Quality, Regulatory & Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
C R BARD INC4.51%17 263
MEDTRONIC PLC6.23%103 898
BAXTER INTERNATIONAL I..5.48%25 439
ZIMMER BIOMET HOLDINGS..11.89%23 129
HOYA CORPORATION-4.35%16 008
TERUMO CORP-3.01%13 900
More Results